Honestly, although Democrats' takeover of the House is the biggest overall headline of the night, its health care implications are pretty modest.
The big picture: The next two years will test the strength of Republicans' alliance with the health care industry, and pharmaceutical companies in particular. "The real test will be, do Republicans vote ‘no’ on this ... when it’s on the floor?" a pharmaceutical lobbyist told Axios after Republicans were largely silent on Trump's latest drug-pricing plan. We're about to find out.